GENITOURINARY, CENTRAL NERVOUS SYSTEM (CNS) TUMORS, SARCOMA AND CANCER OF UNKNOWN PRIMARY SITE GROUP

CLINICAL RESEARCH
Genitourinary, Central Nervous System (CNS) tumors, Sarcoma and Cancer of Unknown Primary Site Program

JOAN CARLES
Principal Investigator
Biosketch

We are dedicated to advancing clinical and translational research against cancer and have extensive experience and expertise in treating various neoplasms. We design and develop clinical trials for genitourinary malignancies at different stages of disease in collaboration with urologists and radiation therapists.

During 2019 we continued to consolidate our expert Prostate Task Force. By closely connecting clinical and translational researchers at VHIO and the Vall d’Hebron Research Institute (VHIR), we have initiated translational projects focused on prostate cancer. We are also doing the same for kidney cancer in pursuit of similar goals in collaboration with other partners including Biomedical Research Institute of Bellvitge (IDIBELL).

Over recent years, several advances have been reported in the more effective treatment of GU malignancies. Immunotherapy (IO) is proving increasingly important against bladder and kidney cancers. Concerning the latter, immune-based therapies in combination with others or paired with antiangiogenics is considered the new standard treatment for first-line therapy. Both approaches have proven more effective compared with antiangiogenic therapy alone.

In bladder cancer immunotherapy has also been shown as superior to chemotherapy in second line and in first-line for ineligible patients. It has recently been shown that immunotherapy in combination with concurrent chemotherapy or as maintenance after 4/6 cycles of chemotherapy in first-line improves progression-free survival (PFS).

Our group –along with others- has observed that immunotherapy could also be effective for certain subgroups of patients with castration-resistant prostate cancer. We are currently participating in phase I studies to assess immune-based cancer medicines for the treatment of this patient population.

We have also participated in various clinical trials using checkpoint inhibitors for the adjuvant treatment of bladder and kidney cancers with high risk of recurrence. Working closely with our Vall d’Hebron University Hospital’s Urology Department and other experts in high-risk tumors, we are currently running studies aimed at improving outcomes for patients with non-muscle- invasive bladder cancer.

We collaborate with various other renowned research centers including the Cleveland Clinic (Ohio, USA), University of California, San Francisco (California, USA). We also participate in studies carried out in partnership with the Gustave Roussy Institute (Paris, France), Barts Health NHS Trust – Hospital (London, UK), and Kantonsspital St. Gallen (Switzerland).

This year we have expanded our translational research program in prostate cancer working alongside VHIO’s Prostate Cancer Translational Research Group, led by Principal Investigator Joaquin Mateo. We have performed 20 biopsies (16 bone and 4 prostate biopsies) and aim to correlate blood samples with these tests.

STRATEGIC GOALS

  • Design and develop clinical trials covering all malignancies studied by our group. We seek to provide our patients with the most novel and optimal treatments including immune-based therapeutics, targeted therapies and new chemotherapies.
  • Conduct clinical trials at different stages of disease with emphasis on a histology-tailored design and multidisciplinary approach.
  • Develop new tools and techniques including liquid biopsy for our patients to more precisely tailor treatments against mCRPC, GIST and kidney cancer.
  • Microbiota studies as a biomarker for immunotherapies to treat bladder and kidney cancers.
  • Consolidate our biopsy program (mainly in bone), for patients with mCRPC to target genomic alterations including PI3K pathways, DNA repair genes, and androgen receptor alterations.
  • Further consolidate our Kidney Cancer Task Force at VHIO in collaboration with researchers at the Vall d’Hebron Research Institute (VHIR) and Biomedical Research Institute of Bellvitge (IDIBELL).
  • Expand our translational research platform for glioblastoma in collaboration with VHIO’s Gene Expression & Cancer Group.
  • Develop our translational platform for GIST and expand research in collaboration with the Spanish Sarcoma Group (GEIS), and other European referral centers. We are also an active member of the European References Network (ERN).

 


HIGHLIGHTS

  • We have consolidated our Task Force and our Serum Bank in Prostate Cancer. This allows us to participate in different translational studies a sell as lead the IRONMAN Project in Spain.
  • Expansion of our Phase I program across all tumor types studied by our group.
  • Fostered and developed new collaborations with different VHIO as well as external research groups.

 


TEAM

  • Principal Investigator
    • Joan Carles
  • Medical Oncologists and Clinical Fellows
    • Macarena Gonzalez
    • Joaquin Mateo
    • Rafael Morales
    • César serrano
    • Cristina Suárez
    • Claudia Valverde
    • Maria Vieito
  • Clinical Nurse Specialist
    • Alexandre Sierra

 


Most relevant scientific publications

  • Slovin S, Clark W, Carles J, Krivoshik A, Park JW, Wang F, George D. Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study. JAMA Oncol. 2018 May 4(5): 702-706.
  • Carles J, Castellano D, Mendez-Vidal MJ, Mellado B, Saez MI, Gonzalez del Alba A, Perez-Gracia JL, Jimenez J, Suarez C, Sepulveda JM, Manneh R, Porras I, Lopez C, Morales-Barrera R, Arranz JA. Circulating tumor cells as a biomarker of survival and response to Radium-223 therapy: Experience in a cohort of patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2018 Dec;16(6):e1133-e1139.
  • Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Eur Urol. 2018 Jul 74 (1): 17-23.
  • Carles J, Pichler A, Korunkova H, Tomova A, Ghosn M, El Karak F, Makdessi J, Koroleva I, Barnes G, Bury D, Ozatilgan A, Hitier S, Katolicka J. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). BJU Int. 2019 Mar;123(3):456-464. Epub 2018 Sep 16.
  • Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017 Oct 1;35(28):3198-3206.
  • García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, Del Alba AG, Castellano D, Gallardo E, Anido U, Del Muro XG, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. Lancet Oncol. 2017 May;18(5):672-681.
  • Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017 Feb;71(2):281-289.
  • Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. Cancer Discov.2017 Jan;7(1):102-113.
  • Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O’Sullivan JM; Radium-223 International Early Access Program Investigators. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016 Sep;17(9):1306-16.
  • Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016 Oct;17(10):1386-1395.
  • Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suárez C, García-Del-Muro X, Carles J, Viñals F, Graupera M, Indraccolo S, Casanovas O. Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Rep. 2016 May 10;15(6):1134-43.
  • Morales-Barrera R, Suárez C, de Castro AM, Racca F, Valverde C, Maldonado X, Bastaros JM, Morote J, Carles J. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Cancer Treat Rev. 2016 Nov; 50: 208-216.
  • Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Srinivas S, Morales-Barrera R, Carles J, Al-Wardat R, Al-Rabi K, Maakoseh M.  Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model. Clin Genitourin Cancer 2016 Jun; 14(3): 255-60
  • Serrano C, Romagosa C, Hernandez-Losa J, Simonetti S, Valverde C, Moliné T, Somoza R, Pérez M, Vélez R, Verges R, Domínguez R, Carles J, Ramón y Cajal S.  RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. Cancer 2016 Jan; 122(1): 99-107
  • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2): 152-60
  • De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejón D, Oliveira M, Arias A, Raventós C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramón y Cajal S, Carles J, Rodón J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J.  Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839
  • Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ.  Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. J. Urol. 2015 Nov; 194(5): 1277-84
  • Suárez C, Morales-Barrera R, Ramos V, Nuñez I, Valverde C, Planas J, Morote J, Maldonado X, Carles J.  Role of immunotherapy in castration-resistant prostate cancer (CRPC). BJU Int. 2014 Mar; 113(3): 367-75
  • Morales-Barrera R, Suárez C, Valverde C, Nuñez I, Maldonado X, Morote J, Carles J.  Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy? Clin Transl Oncol 2014 Jan; 16(1): 102-6
  • Simonetti S, Serrano C, Hernandez-Losa J, Bagué S, Orellana R, Valverde C, Lleonart ME, Aizpurua M, Carles J, Ramón y Cajal S, Romagosa C.  Schwannomas, benign tumors with a senescent phenotype.Histol. Histopathol. 2014 Jun; 29(6): 721-30
  • Prior C, Pérez-Gracia JL, García-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suárez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martínez E, Moreno F, Font A, Calvo A.  Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS ONE 2014; 9(1): e86263

All publications

  • Heidenreich A, Gillessen S, Heinrich D, Keizman D, O’Sullivan JM, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC Cancer2019 19:12.
  • González Del Alba A, De Velasco G, Lainez N, Maroto P, Morales-Barrera R, Muñoz-Langa J, Pérez-Valderrama B, Basterretxea L, Caballero C, Vazquez S. SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer. Clin Transl Oncol. 2019 Jan;21(1):64-74.
  • Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W,Carreira S, Barrero M, Petremolo A, Miranda S, Riisnaes R, Rodrigues DN, Gurel B, Sumanasuriya S, Paschalis A, Sharp A, Mateo J, Tunariu N, Chinnaiyan AM, Pritchard CC, Kelly K, de Bono JS. Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Eur Urol. 2019 Jan;75(1):184-192.
  • Carles J, Gallardo E, Domenech M, Font A, Bellmunt J, Figols M, Mellado B, Saez MI, Suarez C, Mendez MJ, Maroto P, Luque R, de Portugal T, Aldabo R, Bonfill T, Morales-Barrera R, Garcia J, Macia, S, Maldonado X, Foro P. Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):344-352.
  • Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019 Feb 20;37(6):490-503.
  • Font A, Luque R, Villa JC, Domenech M, Vázquez S, Gallardo E, Virizuela JA, Beato C, Morales-Barrera R, Gelabert A, Maciá S, Puente J, Rubio G, Maldonado X, Perez-Valderrama B, Pinto A, Fernández Calvo O, Grande E, Garde-Noguera J, Fernández-Parra E, Arranz JÁ. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). Target Oncol. 2019 Feb;14(1):15-32. Review.
  • Ravegnini G, Sammarini G, Serrano C, Nannini M, Pantaleo MA, Hrelia P, Angelini S. Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. Ther Adv Med Oncol. 2019 Mar 1;11:1758835919831902. Review.
  • Carles J, Pichler A, Korunkova H, Tomova A, Ghosn M, El Karak F, Makdessi J, Koroleva I, Barnes G, Bury D, Ozatilgan A, Hitier S, Katolicka J. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).BJU Int.2019 Mar;123(3):456-464.
  • Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith M, ARAMIS Investigators. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med2019; 380:1235-1246.
  • O’Sullivan JM, Carles J, Cathomas R, Gomez-Iturriaga A, Heinrich, D,  Kramer G, Ost P, van Oort I, Tombal B. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. Eur Urol Oncol. 2019 Mar 25. pii: S2588-9311(19)30031-8.
  • Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suárez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Curr Oncol Rep.2019 Mar 27;21(5):42.
  • Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 Mar;75(3):368-373.
  • Morales-Barrera R, Suárez C, Mateo J, González M, Carles J. Nanoparticles as theranostic vehicles in prostate cancer. Ann Transl Med. 2019 Mar;7(Suppl 1):S29.
  • Serrano C, Marino-Enriquez Adrian, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 Mar;120(6):612-620.
  • Ravegnini G, Serrano C, Simeon V, Sammarini G, Nannini M, Roversi E, Urbini M, Ferre F, Ricci R, Tarantino G, Pantaleo MA, Hrelia P, Angelini S. The rs17084733 variant in the KIT 3′ UTR tumour: a sponge-like mechanism conferring disease susceptibility. Epigenetics. 2019 Jun;14(6):545-557.
  • Serrano C, Garcia del Muro X, Valverde C, Sebio A, Duran J, Manzano A, Pajares I, Hindi N, Landolfi S, Jimenez Laura, Rubio-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Diaz-Beveridge R, Martinez-Marin V, Vicente-Baz D, Vivancos A, Hernandez-Losa J, Arribas J, Carles J. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. Oncologist. 2019 May;24(5):680-687.
  • Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Onc.May 2019; 37 (13): 1051-/+.
  • Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Curr Oncol Rep. 2019 May 27; 21 (5): 42. doi: 10.1007/s11912-019-0790-6. Review.
  • Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. Oncologist. May 2019; 24 (5): 680-687.
  • Abida W CJ, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera J, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Rodrigues DN, Loda M, Gopalan A, Pritchard CC, Colin C, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Howard I, Kantoff PW, Taplin ME, Schultz N, de Bono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL, Sawyers Charles L. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. Jun 2019; 116 (23): 11428-11436.
  • Martin-Broto J, Hindi N, Cruz J, Martinez-Trufero J, Valverde C, De Sande LM, Sala A, Bellido L, De Juan A, Rubió-Casadevall J, Diaz-Beveridge R, Cubedo R, Tendero O, Salinas D, Gracia I, Ramos R, Baguè S, Gutierrez A, Duran-Moreno J, Lopez-Pousa A. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). Oncologist. Jun 2019 24 (6):e338-e346.
  • Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero L, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, Seoane J. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun.Jun 2019; 10 2416.
  • Procopio G, Bamias A, Schmidinger M, Hawkins R, Sánchez AR, Estevez SV, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Rodriguez CS, Jonasch E. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. Clin Gen Can. Jun 2019; 17(3): E526-E533
  • Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ, IMmotion151 Study Group. (2019). Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. Jun 2019; 393 (10189): 2404-2415.
  • Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y,  Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O’Hagan A, Avadhani A; Siefker-Radtke A O; BLC2001 Stud y Grp. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. Jul 2019; 381 (4): 338-348.
  • Serrano C, Marino-Enriquez A, Tao DL, Ketzer J, Eilers G, Zhu MJ, Yu CN, Mannan AM, Rubin BP, Demetri GD, Raut CP, Chandrajit P, Presnell A, McKinley A, Heinrich MC, Michael C, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer.2019 Mar;120(6):612-620. Correction.
  • Saad F, Gillessen S, Heinrich D, Keizman D, O’Sullivan JM, Nilsson S, Miller K, Wirth Ma, Reeves M; Carles J, Heidenreich A. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Clin Gen Can. Oct 2019, 17 (5): 348+/-.
  • Marín-Aguilera M, Reig Ò, Milà-Guasch M, Font A, Domènech M, Rodríguez-Vida A, Carles J, Suárez C, Del Alba AG, Jiménez N, Victoria I, Sala-González N, Ribal MJ, López S, Etxaniz O, Anguera G, Maroto P, Fernández PL, Prat A, Mellado B. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer. Int J Cancer.2019 Oct; 145 (7): 1970 – 1981.
  • Mateo J, Carreira S, de Bono JS. PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. Eur Urol. Oct 2019; 76 (4): 459-460.
  • Pérez-Gracia JL, Castellano D, Climent MÁ, Mellado B, Suárez C. Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. Med Oncol. 2019 Mar; 19; 36 (3):29.
  • Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019 Nov; 25(11): 1706-1714.
  • Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, Aversa C, Figueiredo I, Fraser J, Ahmad Z, Lu CX, Rescigno P, Kolinsky M, Bertan C, Seed G, Riisnaes R, Miranda S, Crespo M, Pereira R, Ferreira A, Fowler G, Ebbs B, Flohr P, Neeb Antje, Bianchini D, Petremolo A, Sumanasuriya S, Paschalis A, Mateo J, Tunariu N, Yuan W,  Carreira S, Plymate SR, Luo J, de Bono JS. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Eur Urol. Nov 2019; 76 (5): 676-685.
  • De Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C,Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B,  Sverrisdottir A, Theodore C,  Feyerabend S, Helissey C, Ozatilgan  A, Geffriaud-Ricouard C, Castellano D, CARD Investigators. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. Dec 2019; 381 (26): 2506-2518.
  • Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors. Cancer. 2019, Dec 12. doi: 10.1002/cncr.32645. [Epub ahead of print].
  • Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen  J, Triplett O, Marino-Enriquez A,  Wagner Andrew J, Demetri GD, Velculescu VE, Paweletz C,  Fletcher JA, George S. Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine kinase inhibitor refractory gastrointestinal stromal tumors. Clin Can Res. Dec 2019; 25 (24): 7287 – 7293.
  • George S, Serrano C, Hensley ML, Ray-Coquard I. Soft Tissue and Uterine Leiomyosarcoma. J Clin Oncol. 2018 Jan 10;36(2):144-150.
  • Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M. SEOM clinical guidelines for the treatment of metastatic prostate cancer. 2018 Jan; 20 (1): 110-111.
  • Carles J, Méndez MJ, Pinto Á, Sáez MI, Arranz JA, Maroto P, López-Criado P, Mellado B, Donas JG, Hernando S, León L, Del Alba AG, Laínez N, Esteban E, Reynés G, Pérez-Gracia JL, Germà JR, López-Brea M, Pérez-Valderrama B, Moretones C, Castellano D. Radium-223 international early access program: results from the Spanish subset. Future Oncol. 2018 Jan;14(1):41-50.
  • Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, Suárez C. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):47-56.
  • Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Saad F, Chi KN. Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. Clin Genitourin Cancer. 2018 Feb 16 (1): 72.
  • Morales-Barrera R, González M, Suárez C, Carles J. Detection of circulating tumor DNA for advanced bladder cancer: where are we going? Transl Androl Urol. 2018 Mar;7(Suppl 1):S101-S103. doi: 10.21037/tau.2018.01.0
  • Martínez-Ricarte F, Mayor R, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA, López-Bigas N, Ramon Y Cajal S, Vieito M, Carles J, Tabernero J, Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. Clin Cancer Res. 2018 Jun 15;24(12):2812-2819. doi: 10.1158/1078-0432.CCR-17-3800. Epub 2018 Apr 3
  • Kasper B, Lecointe-Artzner E, Wait S, Boldon S, Wilson R, Gronchi A, Valverde C, Eriksson M, Dumont S, Drove N, Kanli A, Wartenberg M.. Working to improve the management of sarcoma patients across Europe: a policy checklist. BMC Cancer. 2018 Apr 16;18(1):424. doi: 10.1186/s12885-018-4320-y.
  • Moura DS, Ramos R, Fernandez-Serra A, Serrano T, Cruz J, Alvarez-Alegret R, Ortiz-Duran R, Vicioso L, Gomez-Dorronsoro ML, Garcia Del Muro X, Martinez-Trufero J, Rubio-Casadevall J, Sevilla I, Lainez N, Gutierrez A, Serrano C, Lopez-Alvarez M, Hindi N, Taron M, López-Guerrero JA, Martin-Broto J. Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. 2018 Apr 3;9(25):17576-17588.
  • Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A,Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 2018 Apr 378 (15): 1408 – 1418.
  • Slovin S, Clark W, Carles J, Krivoshik A, Park JW, Wang F, George D. Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study. JAMA Oncol. 2018 May 4(5): 702-706.
  • Paumard-Hernández B, Calvete O, Inglada Pérez L, Tejero H, Al-Shahrour F, Pita G, Barroso A, Triviño JC, Urioste M, Valverde C, González Billalabeitia E, Quiroga V, Rodríguez Moreno JF, Fernández Aramburo A, López C, Maroto P, Sastre J, Juan Fita MJ, Duran I, Lorenzo-Lorenzo I, Iranzo P, García Del Muro X, Ros S, Zambrana F, Autran AM, Benítez J. Whole Exome Sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer.Int J Cancer. 2018 May 15. doi: 10.1002/ijc.31604.
  • Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard C, et al. Clinical outcome of prostate cancer patients with germline DNA repair mutations: follow-up from an international study. European Urology. May 2018, Vol 73 (5): 687-693. doi:10.1016/j.euro.2018.01.010
  • Matamalas A, Valverde C, Benavente S, Casas-Gomila L, Romagosa C, González-Tartière P, Pellisé F. Team Approach: Metastatic Disease of the Spine.JBJS Rev. 2018 May;6(5):e6. doi: 10.2106/JBJS.RVW.17.00118.
  • Martinez-Ricarte F, Mayor R Martinez-Saez E, Rubio-Perez C, Pineda E, Cordero E, Cicuendez M, Poca MA, Lopez-Bigas N, Ramon y Cajal S,  Vieito M, Carles J,  Tabernero J, Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. Clin Can Res 2018 Jun 24(12): 2812 – 2819.
  • McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Jun; 24(6):749-757.
  • Suárez C, Campayo M, Bastús R, Castillo S, Etxanitz O, Guix M, Sala N, Gallardo E. Prognostic and Predictive Factors for Renal Cell Carcinoma. Target Oncol. 2018 Jun;13(3):309-331
  • Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos RF, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martín-Broto. Nilotinib as co-adjuvant treatment with doxorubicin in patients with sarcomas: A phase I trial of the Spanish Group for Research on Sarcoma J. Clin Cancer Res. 2018 Jul 23; 24 (21): 5239-5249. doi: 10.1158/1078-0432.CCR-18-0851.
  • Carles J, Castellano D, Mendez-Vidal MJ, Mellado B, Saez MI, Gonzalez del Alba A, Perez-Gracia JL, Jimenez J, Suarez C, Sepulveda JM, Manneh R, Porras I, Lopez C, Morales-Barrera R, Arranz JA. Circulating tumor cells as a biomarker of survival and response to Radium-223 therapy: Experience in a cohort of patients with metastatic castration-resistant prostate cancer. Clin Gen Cancer 2018 Jul 10.1016/j.clgc.2018.07.013
  • Lorente, D, Olmos D, Mateo J et al. Circulating tumur cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of Oncology; Jul 2018 . 29-7, pp.1554-1560.
  • Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Eur Urol Jul 2018 Jul 74(1): 17-23.
  • Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. Oncologist. 2018 Aug 20. pii: theoncologist.2018-0032.
  • Serrano-Candelas E, Ainsua-Enrich E, Navinés-Ferrer A, Rodrigues P, García-Valverde A, Bazzocco S, Macaya I, Arribas J, Serrano C, Sayós J, Arango D, Martin M. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth. Mol Oncol. 2018 Aug;12(8):1383-1397.
  • Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, Aug 2018, 29-9: 1895-1902.
  • Carles J, Pichler A, Korunkova H, Tomova A, Ghosn M, El Karak F, Makdessi J, Koroleva I, Barnes G, Bury D, Ozatilgan A, Hitier S, Katolicka J. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). BJU International. 2018 Ago 10.1111/bju.14509.
  • Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M, Grande E, Suárez C, Markby DW, Arroyo A, Dean M, Choueiri TK, George D. Outcomes based on prior therapy in the phase METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.Br J Cancer.2018 Sep; 119(6):663-669.
  • Martin-Broto J, Hindi N, Cruz J, Martinez-Trufero J, Valverde C, De Sande LM, Sala A, Bellido L, De Juan A, Rubió-Casadevall J, Diaz-Beveridge R, Cubedo R, Tendero O, Salinas D, Gracia I, Ramos R, Baguè S, Gutierrez A, Duran-Moreno J, Lopez-Pousa A. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). Oncologist. 2018 Nov 8. pii: theoncologist.2018-0121. doi: 10.1634/theoncologist.2018-0121. PMID:3040979
  • Nava-Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros M, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer, J Clin Inv, Nov 2018; 128-11, pp.5185-5185.
  • Boysen G, Nava Rodrigues D, Rescigno P, Seed G, Dolling DI, Riisnaes R, Crespo M, et al. SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity. Clin Can Res; Nov 2018; 24-22: 5585-5593.
  • Carles J, Castellano D, Méndez-Vidal MJ, Mellado B, Saez MI, González Del Alba A, Perez-Gracia JL, Jimenez J, Suárez C, Sepúlveda JM, Manneh R, Porras I, López C, Morales-Barrera R, Arranz JÁ. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2018 Dec;16(6):e1133-e1139. doi: 10.1016/j.clgc.2018.07.013. Epub 2018 Jul 21.
  • Delanoya N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A ; Thomson A; Krainer M; Guillot A; De Giorgi U ; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymards JC; Oudarda S. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. European Urology Oncology Volume 1, Issue 6, December 2018, Pages 467-475.
  • Racca F, Morales-Barrera R, Suárez C, Serrano C, Valverde C, Carles J. Vías de señalización del cáncer: Oncogenes. Nefrologia Sup Ext 2018;9(1):2-5
  • Slovin S, Clark W, Carles J , Krivoshik A, Park JW, Wang F, George D. Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study. JAMA Oncol. 2017 Dec 7. doi: 10.1001/jamaoncol.2017.3361. [Epub ahead of print]
  • Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I, Théodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS.  Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.  Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31015-1. doi: 10.1016/j.eururo.2017.11.023. [Epub ahead of print]
  • Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, Ferrer R, Carles J, Regis L. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clin Genitourin Cancer. 2017 Nov 30. pii: S1558-7673(17)30341-5. doi: 10.1016/j.clgc.2017.10.025. [Epub ahead of print]
  • Rodriguez-Vida A, Torregrosa MD, Pinto Á, Climent MÁ, Olmos D, Carles J . Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223. Clin Transl Oncol. 2017 Nov 2. doi: 10.1007/s12094-017-1785-0. [Epub ahead of print] Review.
  • Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, Suárez C. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol. 2017 Nov 13. doi: 10.1007/s12094-017-1765-4. [Epub ahead of print]
  • Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M. Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.Invest New Drugs. 2017 Nov 27. doi: 10.1007/s10637-017-0546-9. [Epub ahead of print]
  • Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Eur Urol. 2017 Sep 20. pii: S0302-2838(17)30728-5. doi: 10.1016/j.eururo.2017.08.035. [Epub ahead of print]
  • Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Saad F, Chi KN. Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. Clin Genitourin Cancer. 2017 Jul 25. pii: S1558-7673(17)30211-2. doi: 10.1016/j.clgc.2017.07.014. [Epub ahead of print]
  • Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study. Eur Urol Focus. 2017 Mar 31. pii: S2405-4569(17)30079-2. doi: 10.1016/j.euf.2017.03.011. [Epub ahead of print]
  • Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N, Lopez-Pousa A. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Ann Oncol. 2017 Dec 1;28(12):2994-2999
  • Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Alvarez R, Martinez-Trufero J, Lopez-Martin JA, Correa R, Cruz J, Lopez-Pousa A, Santos A, García Del Muro X, Martin-Broto J. Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemother Pharmacol. 2017 Dec;80(6):1113-1131
  • Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3.
  • Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017 Oct 1;35(28):3198-3206.
  • Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. Br J Cancer. 2017 Oct 24;117(9):1278-1285
  • Mora J, Castañeda A, Perez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, Martin-Broto J, Garcia Del Muro X, Cruz O, Cruz J, Martinez-Trufero J, Maurel J, Vaz MA, de Alava E, de Torres C. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). Br J Cancer. 2017 Sep 5;117(6):767-774.
  • Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Vis DJ, Srinivas S, Morales-Barrera R, Carles J, Al-Rimawi D, Lee S, Kim KH, Izumi K, Lewin J. Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies. Clin Genitourin Cancer. 2017 Aug;15(4):e563-e571.
  • Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera MB, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh AJM, Pujol E, Perez-Gracia JL, González Larriba JL, Collado R, Los M, Maciá S, De Wit R; SOGUG and DUOS. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Ann Oncol. 2017 Jul 1;28(7):1517-1522
  • Serrano C, George S, Valverde C, Olivares D, García-Valverde A, Suárez C, Morales-Barrera R, Carles J. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Target Oncol. 2017 Jun;12(3):277-288.
  • García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, Del Alba AG, Castellano D, Gallardo E, Anido U, Del Muro XG, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J.  Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. Lancet Oncol. 2017 May;18(5):672-681.
  • González Del Alba A, Arranz JÁ, Puente J, Méndez-Vidal MJ, Gallardo E, Grande E, Pérez-Valderrama B, González-Billalabeitia E, Lázaro-Quintela M, Pinto Á, Lainez N, Piulats JM, Esteban E, Maroto Rey JP, García JA, Suárez C.Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Crit Rev Oncol Hematol. 2017 May;113:171-190.
  • Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, Del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM; SOGUG (Spanish Oncology Genitourinary Group). Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. Oncotarget. 2017 May 2;8(18):30410-30421
  • Martin-Broto J, Martinez-Marín V, Serrano C, Hindi N, López-Guerrero JA, Ramos-Asensio R, Vallejo-Benítez A, Marcilla-Plaza D, González-Cámpora R. Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis.Clin Transl Oncol. 2017 May;19(5):536-545.
  • Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Estrem ST, Lahn MM, Wick W.  Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. Int J Mol Sci. 2017 May 6;18(5)
  • Poveda A, García Del Muro X, López-Guerrero JA, Cubedo R, Martínez V, Romero I, Serrano C, Valverde C,Martín-Broto J; GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research). GEIS guidelines for gastrointestinal sarcomas (GIST). Cancer Treat Rev. 2017 Apr;55:107-119.
  • Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J. Unveiling changes in the landscape of patient populations in cancer early drug development. Oncotarget. 2017 Feb 21;8(8):14158-14172. Review
  • Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017 Feb;71(2):281-289.
  • Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Strategies to design clinical studies to identify predictive biomarkers in cancer research.Cancer Treat Rev. 2017 Feb;53:79-97
  • Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martinez-Ricarte F, Rodon J, Auger C, Aizpurua M, Salas-Puig J, Santamarina E, Martinez-Saez E. Epileptic features and survival in glioblastomas presenting with seizures. Epilepsy Res. 2017 Feb;130:1-6.
  • Regis L, Planas J, Carles J, Maldonado X, Comas I, Ferrer R, Morote J. Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone. Prostate. 2017 Jan;77(1):114-120.
  • Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. Cancer Discov. 2017 Jan;7(1):102-113.
  • Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, García-Carbonero I, Esteban E, Sáez MI, Villatoro R, Suárez C, Carrato A, Munárriz-Ferrándiz J, Basterrechea L, García-Alonso M, González-Larriba JL, Perez-Valderrama B, Cruz-Jurado J, González Del Alba A, Moreno F, Reynés G, Rodríguez-Remírez M, Boni V, Mahillo-Fernández I, Martin Y, Viqueira A, García-Foncillas J. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. Sci Rep. 2017 Jan 24;7:41371
  • Gonzalez-Billalabeitia E, Castellano D, Sobrevilla N, Guma J, Hervas D, Luengo MI, Aparicio J, Sanchez-Muñoz A, Mellado B, Saenz A, Valverde C, Fernandez A, Margeli M, Duran I, Fernandez S, Sastre J, Ros S, Maroto P, Manneh R, Cerezuela P, Carmona-Bayonas A, Ayala de la Peña F, Aguilar JL, Rivera S, García del Muro X, Germà-Lluch JR; Spanish Germ Cell Cancer Group/Grupo Germinal (SGCCG). Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.J Natl Cancer Inst. 2017 Jan 25;109(4)
  • Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, Cruz J, Mulet-Margalef N, Narvaez JA, Martinez Tirado O, Valverde C, Verges R, Viñals J, Martin-Broto J; Spanish Group for Research on Sarcoma.  Cancer Chemother Pharmacol. 2016 Jan;77(1):133-46.
  • RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. Serrano C, Romagosa C, Hernández-Losa J, Simonetti S, Valverde C, Moliné T, Somoza R, Pérez M, Vélez R, Vergés R, Domínguez R, Carles J, Ramón Y Cajal S. Cancer. 2016 Jan 1;122(1):99-107.
  • A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. Mesía R, Vázquez S, Grau JJ, García-Sáenz JA, Lozano A, García C, Carles J, Irigoyen A, Mañós M, García-Paredes B, del Barco E, Taberna M, Escobar Y, Cruz JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).  Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):289-96.
  • Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D.  BMC Cancer. 2016 Feb 22;16:135.
  • Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. Puente J, García Del Muro X, Pinto Á, Láinez N, Esteban E, Arranz JÁ, Gallardo E, Méndez MJ, Maroto P, Grande E, Suárez C.  Target Oncol. 2016 Apr;11(2):129-4.
  • Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Pérez-Valderrama B, Arranz Arija JA, Rodríguez Sánchez A, Pinto Marín A, Borrega García P, Castellano Gaunas DE, Rubio Romero G, Maximiano Alonso C, Villa Guzmán JC, Puertas Álvarez JL, Chirivella González I, Méndez Vidal MJ, Juan Fita MJ, León-Mateos L, Lázaro Quintela M, García Domínguez R, Jurado García JM, Vélez de Mendizábal E, Lambea Sorrosal JJ, García Carbonero I, González del Alba A, Suárez Rodríguez C, Jiménez Gallego P, Meana García JA, García Marrero RD, Gajate Borau P, Santander Lobera C, Molins Palau C, López Brea M, Fernández Parra EM, Reig Torras O, Basterretxea Badiola L, Vázquez Estévez S, González Larriba JL. Ann Oncol. 2016 Apr;27(4):706-11.
  • Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. Agarwal N, Machiels JP, Suárez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M. Oncologist. 2016 May;21(5):535-6.
  • Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suárez C, García-Del-Muro X, Carles J, Viñals F, Graupera M, Indraccolo S, Casanovas O.  Cell Rep. 2016 May 10;15(6):1134-43.
  • Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model. Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Srinivas S, Morales-Barrera R, Carles J, Al-Wardat R, Al-Rabi K, Maakoseh M. Clin Genitourin Cancer. 2016 Jun;14(3):255-60.
  • Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models. López de Maturana E, Picornell A, Masson-Lecomte A, Kogevinas M, Márquez M, Carrato A, Tardón A, Lloreta J, García-Closas M, Silverman D, Rothman N, Chanock S, Real FX, Goddard ME, Malats N; SBC/EPICURO Study Investigators.  BMC Cancer. 2016 Jun 3;16:351.
  • Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. Maurel J, López-Pousa A, Calabuig S, Bagué S, Del Muro XG, Sanjuan X, Rubió-Casadevall J, Cuatrecasas M, Martinez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Lainez N, Rubini M, García-Albéniz X, Martín-Broto J, de Alava E.  Clin Sarcoma Res. 2016 Jun 29;6:10.
  • Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment. Masson-Lecomte A, López de Maturana E, Goddard ME, Picornell A, Rava M, González-Neira A, Márquez M, Carrato A, Tardon A, Lloreta J, Garcia-Closas M, Silverman D, Rothman N, Kogevinas M, Allory Y, Chanock SJ, Real FX, Malats N; SBC/EPICURO Study Investigators.  Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1144-50.
  • A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Lahn MM, Wick W. Neuro Oncol. 2016 Aug;18(8):1146-56.
  • Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O’Sullivan JM; Radium-223 International Early Access Program Investigators. Lancet Oncol. 2016 Sep;17(9):1306-16.
  • Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M. Lancet Oncol. 2016 Oct;17(10):1386-1395.
  • Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Morales-Barrera R, Suárez C, de Castro AM, Racca F, Valverde C, Maldonado X, Bastaros JM, Morote J, Carles J. Cancer Treat Rev. 2016 Nov; 50: 208-216.
  • Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy. Planas J, Celma A, Placer J, Maldonado X, Trilla E, Salvador C, Lorente D, Regis L, Cuadras M, Carles J, Morote J. Actas Urol Esp. 2016 Nov;40(9):549-555.
  • SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016). Poveda A, Martinez V, Serrano C, Sevilla I, Lecumberri MJ, de Beveridge RD, Estival A, Vicente D, Rubió J, Martin-Broto J.Clin Transl Oncol. 2016 Dec;18(12):1221-1228.
  • SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, Garcia Del Muro X.  Clin Transl Oncol. 2016 Dec;18(12):1213-1220.
  • Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Srinivas S, Morales-Barrera R, Carles J, Al-Wardat R, Al-Rabi K, Maakoseh M.  Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model. Clin Genitourin Cancer 2016 Jun; 14(3): 255-60
  • Serrano C, Romagosa C, Hernandez-Losa J, Simonetti S, Valverde C, Moliné T, Somoza R, Pérez M, Vélez R, Verges R, Domínguez R, Carles J, Ramón y Cajal S.  RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. Cancer 2016 Jan; 122(1): 99-107
  • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2): 152-60
  • De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejón D, Oliveira M, Arias A, Raventós C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramón y Cajal S, Carles J, Rodón J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J.  Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839
  • Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ.  Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. J. Urol. 2015 Nov; 194(5): 1277-84
  • Suárez C, Morales-Barrera R, Ramos V, Nuñez I, Valverde C, Planas J, Morote J, Maldonado X, Carles J.  Role of immunotherapy in castration-resistant prostate cancer (CRPC). BJU Int. 2014 Mar; 113(3): 367-75
  • Morales-Barrera R, Suárez C, Valverde C, Nuñez I, Maldonado X, Morote J, Carles J.  Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy? Clin Transl Oncol 2014 Jan; 16(1): 102-6
  • Simonetti S, Serrano C, Hernandez-Losa J, Bagué S, Orellana R, Valverde C, Lleonart ME, Aizpurua M, Carles J, Ramón y Cajal S, Romagosa C.  Schwannomas, benign tumors with a senescent phenotype.Histol. Histopathol. 2014 Jun; 29(6): 721-30
  • Prior C, Pérez-Gracia JL, García-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suárez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martínez E, Moreno F, Font A, Calvo A.  Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS ONE 2014; 9(1): e86263
  • Castellano DE, Bellmunt J, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suárez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J. Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemother. Pharmacol. 2014 Apr; 73(4): 857-67
  • Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F.  Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. 2014 Nov; 66(5): 815-25
  • Foro P, Algara M, Lozano J, Rodriguez N, Sanz X, Torres E, Carles J, Reig A, Membrive I, Quera J, Fernandez-Velilla E, Pera O, Lacruz M, Bellosillo B.  Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 2014 Apr; 88(5): 1057-63
  • Morote J, Planas J, Maldonado X, Carles J.  Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest. Actas Urol Esp 2014 Sep; 38(7): 419-20
  • Bellmunt J, Suárez C, Gallardo E, Rodón J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J.  Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist 2014 Sep; 19(9): 917-8
  • Morote J, Celma A, Planas J, Placer J, de Torres I, Olivan M, Carles J, Reventos J, Doll A.  Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci 2014; 15(8): 13615-23
  • Serrano C, Simonetti S, Hernandez-Losa J, Valverde C, Carrato C, Bagué S, Orellana R, Somoza R, Moliné T, Carles J, Huguet P, Romagosa C, Ramón y Cajal S.  BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours. Histopathology 2013 Feb; 62(3): 499-504
  • Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventos J, Doll A.  Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2013 Jun; 111(7): 1031-6
  • Mesia R, Rueda A, Vera R, Lozano A, Medina JA, Aguiar D, Árias F, Triana G, Carles J, Lopez-Lopez R.  Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial. Ann. Oncol. 2013 Feb; 24(2): 448-53
  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE.  Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 2013 Jan; 368(2): 138-48
  • de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vazquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br. J. Cancer 2013 Jun; 108(12): 2565-72
  • Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Álvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vazquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J.  Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.Br. J. Cancer 2013 Jul; 109(1): 121-30
  • Serrano C, Morales R, Suárez C, Nuñez I, Valverde C, Rodón J, Humbert J, Padrós O, Carles J. Emerging therapies for urothelial cancer. Cancer Treat. Rev. 2012 Jun; 38(4): 311-7
  • Castellano D, Carles J, Esteban E, Trigo JM, Climent MA, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz JA, Bellmunt J.  Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treat. Rev. 2012 Aug; 38(5): 431-41
  • Carles J, Castellano D, Climent MA, Maroto P, Medina R, Alcaraz A.  Castration-resistant metastatic prostate cancer: current status and treatment possibilities. Clin Transl Oncol 2012 Mar; 14(3): 169-76
  • Carles J, Chirivella I, Climent MA, Gallardo E, Gonzalez Del Alba A, Maroto JP, Mellado B, García del Muro FX.  Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment. Cancer Metastasis Rev. 2012 Sep; 31 Suppl 1: S3-9
  • Morales-Barrera R, Bellmunt J, Suárez C, Valverde C, Guix M, Serrano C, Gallen M, Carles J.  Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur. J. Cancer 2012 Aug; 48(12): 1816-21
  • Cózar JM, Solsona E, Morote J, Miñana B, Maroto JP, Gonzalez Del Alba A, Climent MA, Carles J, Alcaraz A, Castellano D.  [Recomendations on the management of controversies in advanced castrate-resistant prostate cancer]. Actas Urol Esp 2012; 36(10): 569-77
  • Alcaraz A, Medina R, Maroto P, Climent MA, Castellano D, Carles J.  [Castration-resistant prostate cancer: where are we going?]. Actas Urol Esp 2012 Jun; 36(6): 367-74
  • Morales R, Font A, Carles J, Isla D.  SEOM clinical guidelines for the treatment of invasive bladder cancer. Clin Transl Oncol 2011 Aug; 13(8): 552-9
  • Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Pérez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A.  Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann. Oncol. 2011 Dec; 22(12): 2646-53
  • Morales-Barrera R, Valverde C, Rodón J, Pérez J, Maldonado X, Suárez C, Trilla E, Carles J.  Bilateral testicular germ cell tumours: a single hospital experience. Clin Transl Oncol 2010 Apr; 12(4): 299-302
  • Carles J, Nogué M, Sole JM, Foro P, Domènech M, Suarez M, Gallardo E, García D, Ferrer F, Gelabert-Mas A, Gayo J, Fabregat X.  Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010 Mar; 76(4): 1085-91
  • Serrano C, Suárez C, Andreu J, Carles J.  Acute aortic dissection during sorafenib-containing therapy.Ann. Oncol. 2010 Jan; 21(1): 181-2
  • Pérez-García J, Morales R, Valverde CM, Rodón J, Suárez C, Semidey ME, Garcia-Patos V, Bartralot R, Serra M, Carles J.  Eccrine porocarcinoma presenting with scrotal lymphedema: a case report and review of systemic treatment. Ann. Oncol. 2010 Apr; 21(4): 907
  • Bellmunt J, Maroto-Rey P, Trigo JM, Carles J, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L.  A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clin Transl Oncol 2010 Jul; 12(7): 503-8
  • Suárez C, Morales R, Muñoz E, Rodón J, Valverde CM, Carles J.  Molecular basis for the treatment of renal cell carcinoma. Clin Transl Oncol 2010 Jan; 12(1): 15-21
  • Bellmunt J, Trigo JM, Calvo E, Carles J, Pérez-Gracia JL, Rubió J, Virizuela JA, López R, Lázaro M, Albanell J.  Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010 Apr; 11(4): 350-7
  • Carles J, Morales R, Perez JM, Suárez C, Rodón J, Valverde C.  Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities. Eur. J. Cancer 2009 Sep; 45 Suppl 1: 309-17
  • Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 2009 Sep; 27(27): 4454-61
  • Bellmunt J, Macià F, Malmusi D, Llorente JA, Carles J, Lloreta J, Foro P, Gelabert A, Albanell J, Castells X.  Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. Eur. J. Cancer 2009 Nov; 45(16): 2804-9
  • Bellmunt J, Carles J, Albanell J.  Predictive modelling in hormone-refractory prostate cancer (HRPC). Clin Transl Oncol 2009 Feb; 11(2): 82-5
  • Martínez P, Valverde C, Morales R, Rodón J, Suárez C, Baselga J, Carles J.  Docetaxel activity in second line treatment for urothelial carcinoma: a retrospective analysis European Journal of Cancer Supplements 2009 September; 7(2): 448
  • Carles J, Font A, Mellado B, Domènech M, Gallardo E, González-Larriba JL, Catalan G, Alfaro J, Gonzalez Del Alba A, Nogué M, Lianes P, Tello JM.  Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br. J. Cancer 2007 Nov; 97(9): 1206-10
  • Carles J, Esteban E, Climent M, Font A, González-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J.  Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann. Oncol. 2007 Aug; 18(8): 1359-62